Breaks Categories: News

ThursdayJul 09, 2020 1:07 pm

BioMedNewsBreaks – CRISPR Therapeutics (NASDAQ: CRSP) Secures $517.5M in Underwritten Public Offering

CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, has closed an underwritten public offering of 7,392,857 common shares, including 964,285 additional shares per the full exercise of the over-allotment option granted to the underwriters. CRISPR Therapeutics secured approximately $517.5 million in gross proceeds, with each of the shares sold at the public offering price of $70.00. ROTH Capital Partners acted as co-manager for the offering. For more information, visit www.CRISPRtx.com. About CRISPR Therapeutics CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its…

Continue Reading

TuesdayJul 07, 2020 12:40 pm

BioMedNewsBreaks – InvestorBrandNetwork Announces Launch of Technology-Driven Communications Platform – BioMedWire

InvestorBrandNetwork (“IBN”), a multifaceted communications organization engaged in connecting public companies to the investment community, today announced the launch of BioMedWire (“BMW”) as part of its sustained effort to provide specialized content distribution via widespread syndication channels. A laser-focused, technology-driven communications platform, BioMedWire is designed to provide the latest updates and information related to emerging market opportunities in the life sciences sector and beyond. “The life sciences sector has delivered incredible remedies and cures, saved and changed lives, and offered some of the greatest investment returns the markets have ever seen. The sector is constantly moving and evolving to meet…

Continue Reading

TuesdayJul 07, 2020 10:47 am

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Completes Acquisition of Quantitative Medicine LLC

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced it has completed its acquisition of Quantitative Medicine LLC (“QM”), a biomedical analytics and computational biology company, in an all-stock transaction valued at approximately $1.8 million. Cofounded by Drs. Robert Murphy and Joshua Kangas, both of Carnegie Mellon University’s Computational Biology Department, QM developed its novel, computational drug-discovery platform CoRETM, an innovative machine learning platform that predicts the main effects of drugs on target molecules that mediate disease, which is expected to dramatically reduce the time, cost and financial…

Continue Reading

WednesdayJun 24, 2020 12:19 pm

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) to Participate Live on “The Big Biz Show”

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced that its CEO and Chairman, Rodney Varner, will be participating in a live interview with the “Big Biz Show,” an Emmy Award winning nationally syndicated TV and radio show, on Thursday, June 25. The Big Biz Show, seen and heard in over 100 million broadcast TV homes, 150 U.S. radio stations and in 175 countries, covers current business events, internet-related issues and other hot topics in the business world. Among several engaging topics, Varner will discuss how Genprex is bridging…

Continue Reading

ThursdayJun 18, 2020 12:22 pm

BioMedNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) TumorGenesis Secures First Commercial Sale of its Unique Ovarian Cancer Cell Media

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that its TumorGenesis division sold its first order of its unique ovarian cancer cell culture media for cancer cells collected from patient derived samples (“PDx”) through its distributor US Biological Corporation. According to the update, the media used to grow the novel and unique ovarian cancer cell lines, licensed by TumorGenesis and its partner, GLG Pharma, are able to retain 95%+ of the DNA and RNA as well as crucial proteomic signatures. “Capturing and culturing and then being able…

Continue Reading

TuesdayJun 16, 2020 12:45 pm

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) and Aldevron Expand Manufacturing Program to Advance Oncoprex(TM)

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced its entry into a new agreement with manufacturing partner Aldevron, LLC for expansion of Genprex’s program for the manufacture of TUSC2 (Tumor Suppressor Candidate 2) plasmid DNA for its lead drug candidate, Oncoprex(TM) immunogene therapy. According to the update, the new agreement provides for production of TUSC2 plasmid DNA, the active agent in Oncoprex, at full commercial scale. “We are pleased with continued progress in the scale-up of our manufacturing processes,” Rodney Varner, chairman and CEO of Genprex, said in…

Continue Reading

TuesdayJun 09, 2020 10:34 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Selected to Join Russell 3000(R) Index

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced that it is scheduled to join the U.S. broad-market Russell 3000 Index, which includes the 3,000 publicly traded companies on the Nasdaq and NYSE exchanges with the largest market capitalizations. According to the update and a preliminary list of additions, Genprex will join the index when FTSE Russell, a leading global index provider, reconstitutes its 2020 indices after the markets close on Friday, June 26, 2020. “The selection of Genprex for the Russell 3000(R) Index will add to the awareness…

Continue Reading

TuesdayJun 09, 2020 9:45 am

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Financial Results for Q1 2020, Provides Business Update

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, on Monday reported financial results for the quarter ended March 31, 2020 and provided a business update. “We remain steadfast in our approach to assembling a portfolio of assets that leverages our unique collection of cancer tumors to develop and market AI-based, predictive models for personalized cancer treatments that improve patient outcomes,” Dr. Carl Schwartz, Predictive Oncology CEO, stated in the news release. “Our collection of more than 150,000 cancer tumors, amassed and curated over a 10-year period, gives us a…

Continue Reading

MondayJun 08, 2020 10:11 am

BioMedNewsBreaks – Genprex, Inc.’s (NASDAQ: GNPX) Chairman and CEO to Present at the MoneyShow June Virtual Event

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced that it will present at the MoneyShow June Virtual Event at 12:50 p.m. EDT on Wednesday, June 10, 2020. According to the update, Genprex’s CEO and Chairman, Rodney Varner, will deliver a company overview and provide updates on its product pipeline, including its lead drug candidate, Oncoprex(TM) immunogene therapy, which received Fast Track Designation from the Food and Drug Administration for its combination therapy with AstraZeneca’s Tagrisso(R). He will also provide an overview of Genprex’s in-licensing of a preclinical gene…

Continue Reading

WednesdayJun 03, 2020 9:32 am

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Acquires Soluble Therapeutics, Inc. and BioDtech, Inc.

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, on Tuesday announced the completion of the acquisitions of two wholly owned subsidiaries of InventaBioTech, Inc., Soluble Therapeutics, Inc. and BioDtech, Inc. Included in the acquisition were certain intellectual property relating to contract research organization (“CRO”) services and technology, certain equipment useful in such services and technology and all other assets of Soluble Therapeutics and BioDtech. In consideration, POAI issued 125,000 shares of common stock and waived all remaining amounts due and payable to the company under a secured promissory note…

Continue Reading